Do you have trouble sleeping in the morning or in the middle of the night? This can affect your risk of developing dementia.

Published Date: 08 Mar 2023

Along with growing evidence of poor sleep and cognitive impairment, a new study has found an association between three measures of sleep and the risk of developing dementia by age 10. ...

Read Full News

Latest News

Nipocalimab in Myasthenia Gravis: Real-World Use, Long-Term Safety, and the Road Ahead Marco Meglio, Leonard Dragone, MD, PhD

Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.

RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial Louie Pasculli

Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.

NeurologyLive® Friday 5 — October 16, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.

FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis Marco Meglio

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease Marco Meglio

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Episode 177: Previewing the 2026 NEALS Annual Meeting Marco Meglio, Jinsy A. Andrews, MD, MSc, Nicholas Maragakis, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]

Todays Updates

ENCORE: Early ALIS Cuts MACLD Recurrence, With Jakko Van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

van Ingen, of Radboud University Medical Center discusses data showing add-on ALIS improved durable culture conversion in newly diagnosed MAC lung disease.

ENCORE ALIS Data Could Reshape First-Line MACLD: Jakko van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

van Ingen, of Radboud University Medical Center, discusses the ENCORE trial's patient-reported endpoint for ALIS in MAC lung disease.

Mepolizumab Cuts COPD Exacerbations Across Smoking Status: Claus Vogelmeier, MD Claus Vogelmeier, MD

Vogelmeier, of Philipps-University of Marburg discusses pooled data showing reduced COPD exacerbations, though most effectively in former smokers.

Examining the Oral Steroid Burden in Asthma and COPD

Examining the Oral Steroid Burden in Asthma and COPD

Short Telomeres Linked to UIP Pattern, Not Fibrosis Extent, in ILD

Short Telomeres Linked to UIP Pattern, Not Fibrosis Extent, in ILD

CHEST 2026: Day 2 Recap — 4 Headlines to Know

CHEST 2026: Day 2 Recap — 4 Headlines to Know

NeurologyLive® Brain Games: October 18, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is biomarkers in multiple sclerosis!

Todays Updates

ENCORE: Early ALIS Cuts MACLD Recurrence, With Jakko Van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

van Ingen, of Radboud University Medical Center discusses data showing add-on ALIS improved durable culture conversion in newly diagnosed MAC lung disease.

ENCORE ALIS Data Could Reshape First-Line MACLD: Jakko van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

van Ingen, of Radboud University Medical Center, discusses the ENCORE trial's patient-reported endpoint for ALIS in MAC lung disease.

Mepolizumab Cuts COPD Exacerbations Across Smoking Status: Claus Vogelmeier, MD Claus Vogelmeier, MD

Vogelmeier, of Philipps-University of Marburg discusses pooled data showing reduced COPD exacerbations, though most effectively in former smokers.

Examining the Oral Steroid Burden in Asthma and COPD

Examining the Oral Steroid Burden in Asthma and COPD

Short Telomeres Linked to UIP Pattern, Not Fibrosis Extent, in ILD

Short Telomeres Linked to UIP Pattern, Not Fibrosis Extent, in ILD

CHEST 2026: Day 2 Recap — 4 Headlines to Know

CHEST 2026: Day 2 Recap — 4 Headlines to Know

NeurologyLive® Brain Games: October 18, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is biomarkers in multiple sclerosis!

Latest News

Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.

Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]

News All Time

Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis Marco Meglio

New 48-week phase 3 data show many patients with generalized myasthenia gravis reached minimal symptom expression on telitacicept, and most who did sustained it.

Individualizing Advanced Therapies in Parkinson Disease: Hubert Fernandez, MD Hubert Fernandez, MD, Louie Pasculli

The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.

This Week on NeurologyLive® — October 12, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Brain Games: October 11, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent therapeutic advances in MS!

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Phase 4 THRIVE Data Highlights Eptinezumab’s Impact on Migraine After Prior CGRP Failure Marco Meglio

Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.

FDA Action Update, September 2026: Approvals, Clearances, and Priority Review Isabella Ciccone, MPH

Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.

Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease Marco Meglio

Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.

CSF Biomarkers Identify Shared LRRK2 Pathway Activation in Sporadic and LRRK2-Associated Parkinson Disease Louie Pasculli

New cerebrospinal fluid biomarker data suggest shared LRRK2 pathway activation across sporadic and LRRK2-associated Parkinson disease, potentially informing biomarker development and therapeutic targeting.

Metabolic Agent Vutiglabridin Improves Motor Scores in Early-Stage Study of Parkinson Disease Marco Meglio

Phase 2a trial results showed 800 mg vutiglabridin significantly improved motor symptom scores compared with placebo in early-stage Parkinson's disease.

Christen Kutz, PhD, PA-C, on What Real-World Data Reveal About Treatment Transitions to Nipocalimab in Generalized Myasthenia Gravis Marco Meglio, Christen Kutz, PhD, PA-C

Christen Kutz, PhD, PA-C, discusses a retrospective survey of neurology providers examining why patients with generalized myasthenia gravis are transitioning to nipocalimab and what real-world outcomes data suggest about its role in the treatment landscape.

New Study Reveals Plasma Biomarkers Highlight Distinct Biological Responses to Lecanemab in Alzheimer Disease Louie Pasculli, Carlos Cruchaga, PhD

Carlos Cruchaga, PhD, director of the NeuroGenomics and Informatics Center at Washington University, discusses emerging blood-based biomarkers for monitoring biological and cognitive responses to lecanemab treatment in Alzheimer disease.

Brain Chat: The Overlap Years: Perimenopause, Menopause, and MS Mitzi Joi Williams, MD

Mitzi Joi Williams, MD, is joined by Jakai McEwen, DO, and Charnetta Colton-Poole, MD, to discuss the challenges of communication between patients and their health care teams, including navigating medical language, promoting shared decision-making, and advocating for clear, patient-centered care.

Advanced Therapies in Parkinson Disease: Matching the Right Treatment to the Right Patient Hubert Fernandez, MD, Louie Pasculli

An MDS 2026 plenary speaker discusses the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease, including when to consider device-aided therapies and how treatment selection can be individualized.

Emerging Advances in Parkinson Disease Ahead of MDS 2026: Benjamin Walter, MD, MBA Benjamin L. Walter, MD, Louie Pasculli

Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson disease care, alongside developments in adaptive deep brain stimulation and efforts to identify disease earlier.

Recommended News For You

Shorter, less intense regimen still effective for HPV-linked throat cancer, study shows

Analysis of NRG trial in limited-stage small cell lung cancer suggests QOL benefit with twice- vs. once-daily radiation

Dissociative identity disorder: method or fact?

Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement

Dual-action mRNA vaccine takes aim at aggressive skin cancer

A computer-aided diagnostic system for improved detection of breast cancer.

Video: How to treat kidney disease?

Recommended Articles For You

Risk Assessment of Bone-Marrow Reserve Under Repeated Physiological Demands 

Emerging Therapies Using Targeted Antibody–Drug Conjugates Against Previously Difficult Tumor Targets 

Unveiling the Complexity of Multiple Myeloma Staging 

Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Is There a Role for Stimulants in Beating Cancer Fatigue?

2.

Un nou sistem de endoscopică imaging are capacitatea de a detecta mai mulți fluorescent tracers.

3.

Prostate cancer screening seems to be improved by PSA, biomarker testing, and MRI combined.

4.

Breast cancer surgery: Study finds overnight hospital stay not important for older patients

5.

Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

1.

Hematology Drug Preparation Safety: Ensuring Efficacy and Reducing Risks in Clinical Practice

2.

Unraveling the Mysteries of Metastasis: Exploring the Latest Advances in Cancer Research

3.

Spatially Targeted Intratumoral Therapeutics: Mechanisms, Clinical Applications, and Future Directions

4.

Targeted Degradation in Leukemia: Mechanisms, Clinical Implications, and Therapeutic Advances

5.

Comprehensive Applications in Hematology for Better Care

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

2.

Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion

3.

Understanding the causes of anemia in adults beyond nutritional deficiencies

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

5.

From Guidelines to Practice: Hematology

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot